Source - LSE Regulatory
RNS Number : 2550Q
ReNeuron Group plc
25 February 2021
 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Appointment of Joint Broker

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Allenby Capital Limited ("Allenby") as joint corporate broker, with immediate effect to work alongside the Company's existing nominated adviser and joint broker, Stifel Nicolaus Europe Limited.

 

Michael Hunt, Chief Financial Officer of ReNeuron, commented: "The Company is pleased to appoint Allenby as its joint corporate broker, which, together with the appointment of Walbrook PR as the Company's new investor relations and PR adviser, will further broaden our investor outreach activities, particularly with regards to private client brokers and retail investors."

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Via Walbrook PR

Michael Hunt, Chief Financial Officer

 

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

 



Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)

Tim Sohal (Sales & Corporate Broking)

+44 (0)20 3328 5656

 

 

Walbrook PR (Media & Investor Relations)
Paul McManus, Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPQZLFLFLLEBBV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Reneuron Group PLC (RENE)

-0.08p (-2.17%)
delayed 05:00AM